Value and Access Strategy
Objectives: To advise on such as clinical programme, reimbursement needs, market access, representational and distribution issues for a novel technology
Therapy Area: Amyotrophic Lateral Sclerosis (ALS)
Client: USA pharma company
Product/Technology: Drug
Scope: 9 countries (Spain, France, Germany, Swe, Ita, NL, UK, Brazil, Australia)
Our Workplan: Primary research with n=36 in market clinical and payer stakeholders using a developed Product Profile explaining the technology and draft clinical protocol, and a core Discussion Guide adapted for the different territories
Project Duration: 13 weeks
Outcome: Guidance provided on all pertinent issues including on clinical programme design and appropriate QoL instrument for clinical study, DRG (diagnosis related groups) issues and actions, price guidance, specific reimbursement processes and activities and suggested in-market prelaunch activities.
Case Studies
TESTIMONIALS
“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”
Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.
“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”
Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma
“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
